Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
MLYS
#1892
Mineralys Therapeutics, Inc. Common Stock
27.320
0
USD
+0.59%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.59%
Monthly Change
+3.96%
6 month change
-32.33%
Year Change
-32.33%
Previous Close
27.160
0
Open
27.320
0
Bid
Ask
Low
27.320
0
High
27.320
0
Volume
83
Markets
US Stock Market
Healthcare
MLYS
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2023
2024
2025
TTM
Key stats
Total common shares outstanding
49.63 M
49.84 M
82.4 M
—
Valuation ratios
Enterprise value
381.49 M
499.39 M
2.82 B
7.27 B
Price to earnings ratio
-4.36
-3.36
-15.85
-36.63
Price to sales ratio
—
—
—
—
Price to cash flow ratio
-3.87
-3.59
-17.24
-37.24
Price to book ratio
1.3
3.12
3.8
6.86
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.29
-0.86
-0.23
-0.36
Return on equity %
-0.3
-0.93
-0.24
-0.38
Return on invested capital %
-7 382.34
-29.95 K
-140.41 K
—
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
23.76
14.02
43.76
110.87
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-2.24
-3.43
-2.1
-2.29
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
6.54
4.08
9.71
29.53
Net current asset value per share
6.88
4.23
9.78
30.06
Tangible book value per share
6.66
3.94
9.56
28.94
Working capital per share
6.59
3.93
9.55
28.92
Book value per share
6.66
3.94
9.56
28.94
News
Jefferies cuts Mineralys Therapeutics price target on drug concerns
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)
Stifel reiterates Buy rating on Mineralys stock, $52 target
BofA raises Mineralys Therapeutics stock price target on NDA progress
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Mineralys earnings in focus as FDA lorundrostat decision looms
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505
Mineralys Therapeutics MLYS officer sells $569k in stock
Rodman sells Mineralys (MLYS) shares for $13,353